



Potent antifungal properties of gallic acid in *Sarcochlamys pulcherrima* against *Candida auris*

NAHID AKHTAR¹, M. AMIN-UL MANNAN^{1,2*}, DEEKSHA PANDEY³, AMON SARKAR¹,
HIMANSHI SHARMA¹, MANISH KUMAR³, ANUP GHOSH⁴

¹Department of Molecular Biology and Genetic Engineering, School of Bioengineering and Biosciences,
Lovely Professional University, Jalandhar-Delhi, India

²Division of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor, University of California
Los Angeles (UCLA) Medical Center, Los Angeles, CA, USA

³Department of Biophysics, University of Delhi-South Campus, New Delhi, India

⁴Department of Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Received: 22 April 2022; revised: 28 September 2022; accepted: 17 January 2023

Abstract

Candida auris is a major public health concern due to its high transmission and mortality rates, as well as the emergence of pan-resistant strains. This study aimed to identify an antifungal compound from *Sarcochlamys pulcherrima*, an ethnomedicinal plant, that can inhibit the growth of *C. auris*. Methanol and ethyl acetate extracts of the plant were obtained, and high-performance thin-layer chromatography (HPTLC) analysis was conducted to identify the major compounds in the extracts. The major compound detected by HPTLC was subjected to *in vitro* antifungal activity testing, and its antifungal mechanism was determined. The plant extracts inhibited the growth of both *C. auris* and *Candida albicans*. HPTLC analysis revealed the presence of gallic acid in the leaf extract. Furthermore, the *in vitro* antifungal assay showed that gallic acid inhibited the growth of different *C. auris* strains. *In silico* studies indicated that gallic acid can bind to the active sites of carbonic anhydrase (CA) proteins in both *C. auris* and *C. albicans*, affecting their catalytic activities. Compounds that target virulent proteins such as CA can aid in the reduction of drug-resistant fungi and the development of novel antifungal compounds with unique modes of action. However, additional *in vivo* and clinical studies are required to conclusively determine gallic acid's antifungal properties. Gallic acid derivatives may be developed in the future to possess more potent antifungal properties and target various pathogenic fungi.

Key words: *Sarcochlamys pulcherrima*, antifungal, gallic acid, *Candida auris*, molecular docking, carbonic anhydrase

Introduction

Candida auris is a fungus that is emerging as a nosocomial pathogen (Chybowska et al., 2020; Sathyapalan et al., 2021). Multidrug-resistant strains of *C. auris* have been reported in over 30 countries worldwide (Chowdhary et al., 2017; Rudramurthy et al., 2017; Adams et al., 2018; Ruiz-Gaitán et al., 2018; Chow et al., 2019; Ademe and Girma, 2020). Resistance to major antifungal drugs

including fluconazole, terbinafine, amphotericin B, and echinocandins has been reported in *C. auris* (Lamoth and Kontoyiannis, 2018; Chybowska et al., 2020). Around 40% of isolates are resistant to at least two antifungals, and 4–10% of isolates are resistant to most antifungals (Lockhart et al., 2017; Lamoth and Kontoyiannis, 2018).

C. auris can infect and colonize humans, especially in hospital settings (Belkin et al., 2018; Dahiya et al., 2020).

* Corresponding author: ¹ Department of Molecular Biology and Genetic Engineering, School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar-Delhi, G.T. Road, Punjab, 144401, India; ² Division of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor, University of California Los Angeles (UCLA) Medical Center, Los Angeles, CA, USA; e-mail: mannan.phd@gmail.com

These nosocomial infections are mostly associated with bacterial biofilm formation (Lamoth and Kontoyiannis, 2018) and can be transmitted between patients in health-care settings, where healthcare personnel could also play a role in their transmission (Forsberg et al., 2019; Du et al., 2020). The fungus mostly affects immunocompromised patients, with mortality rates of up to 60% (Chen et al., 2020). According to the Centers for Disease Control and Prevention in the United States of America, echinocandins such as micafungin, caspofungin, and anidulafungin are recommended for the treatment of *C. auris* infections (Cândido et al., 2020).

Various other drugs, such as azoffluxin in combination with fluconazole, SS750, rocaglate, and colistin with echinocandins, have been shown to inhibit the growth of *C. auris* in different *in vitro* and *in vivo* experiments (Matsumoto et al., 2002; Ruiz-Gaitán et al., 2018; Bidaud et al., 2020; Iyer et al., 2020). Similarly, other drugs like sulfamethoxazole in combination with voriconazole, a low ionic solution formulation of caspofungin, and carvacrol (a polyphenol) have exhibited antifungal properties against *C. auris* (Eldesouky et al., 2018; Shaban et al., 2020; Sumiyoshi et al., 2020). Additionally, hydrogen peroxide vapor, chlorine, iodinated povidone, and chlorhexidine gluconate can kill *C. auris*, which can be beneficial in preventing nosocomial infections and transmissions (Abdolrasouli et al., 2017).

Numerous scientific studies have been conducted to discover novel drugs/phytochemicals to treat *C. auris* infections, but only a few have advanced to the clinical trial stage. Some antifungals that have progressed to clinical trials for *C. auris* include Ibrexafungerp, which inhibits 1,3- β -D-glucan synthesis, MGCD290, a fungal histone deacetylase (HDAC) inhibitor, VT-1129, which interferes with cytochrome P450 activity, and Fosmanogepix (APX001), which inhibits fungal glycosylphosphatidylinositol (GPI) anchor protein (Oliver et al., 2016; Ghannoum et al., 2020; Gintjee et al., 2020; Yu et al., 2020). However, the currently used antifungals such as polyenes, azoles, and echinocandins exert high selective pressure on the pathogen, leading to the development of drug resistance (Srinivasan et al., 2014).

Plants used in traditional and herbal medicine may be a key source of new antifungal compounds. Studies have shown that various herbs possess antimicrobial activity (Akhtar et al., 2017a, 2017b; Choudhury et al., 2017; Sarkar et al., 2021). Therefore, this study evaluated the

antioxidant and antifungal properties of an extract from the ethnomedicinal plant *Sarcochlamys pulcherrima*. *S. pulcherrima* is an evergreen tree that grows in the forests of northeastern states of India, Thailand, Bhutan, Myanmar, and Indonesia (Mazumder et al., 2015), and is used by various tribes in India and Bangladesh to treat several ailments such as fever blisters, tongue ulcers, flatulence, boils, dysentery, diarrhea, digestion problem, and itching of the eyes (Mazumder et al., 2015). The antibacterial and antifungal properties of *S. pulcherrima* have been reported in previous studies (Mazumder et al., 2014; Ghosh et al., 2020).

In this study, prospective antifungals were investigated using the diffusion method, and the molecule was identified using high-performance thin-layer chromatography (HPTLC). The assay showed that gallic acid was one of the prominent molecules present in the *S. pulcherrima* leaves extract. We hypothesized that gallic acid was a potent antifungal and explored its efficacy against *C. auris*. Gallic acid has been found in a variety of plants and has been shown to possess antibacterial and antifungal activities (Li et al., 2017; El-Nagar et al., 2020; Simonetti et al., 2020). Additionally, the potential target of gallic acid in *C. auris* was determined using an *in silico* approach in this study.

The carbonic anhydrase (CA) enzyme can be a potential target for antifungal compounds. CA (EC number 4.2.1.1) is a metalloenzyme that efficiently catalyzes the interconversion of carbon dioxide (CO₂) and bicarbonate (Elleuche and Pöggeler, 2010). It plays a crucial role in virulence in *Cryptococcus* spp. and *C. albicans* (Schlicker et al., 2009; Hall et al., 2010; Dostál et al., 2020; Fasciana et al., 2020), as well as phenotypic switching, sporulation, cAMP concentration increase, and survival in varying CO₂ concentrations within the host (Buck and Levin, 2011; Huang, 2012; Jungbluth et al., 2012; Cummins et al., 2014). Due to its involvement in vital biological processes such as respiration, pH homeostasis, fungal growth, virulence, and CO₂ transport, CA can be a crucial target for developing novel antifungal agents (Elleuche and Pöggeler, 2010; Supuran and Capasso, 2021). Previous studies have also suggested CA as a target for antifungal drugs (Schlicker et al., 2009; Supuran and Capasso, 2021). Therefore, in this study, we used a computational approach to assess whether gallic acid may function by binding with the CA of *C. auris*.

The study's results suggest that gallic acid has the potential to impact the catalytic activity of the CA enzyme in *C. auris* and can be further investigated as a therapeutic agent for treating *C. auris* infections.

Materials and methods

Sample collection and preparation of extract

Leaves and barks from a single *S. pulcherrima* tree were collected from the New Halflong region of North Cachar Hills (Assam, India) in July 2018. The plant samples were washed thoroughly with water to remove any dust and impurities. The samples were air-dried in a hot air oven at 45–50°C until they were completely dry. The dried samples were then ground into a fine powder using a grinder, packed in airtight packets, and stored at 4°C for future use. The extract was obtained through Soxhlet-mediated extraction using two solvents, 90% methanol and ethyl acetate. To obtain the plant extract, 30 g of leaf powder was mixed with 100 ml of each solvent (Padmasree et al., 2017). The Soxhlet apparatus was run at ~65°C (methanol extraction) and ~77°C (ethyl acetate extraction) for 25 cycles (Padmasree et al., 2017). The crude solvent extract was then concentrated to 5 ml using a rotary evaporator at 40 rpm and 50°C temperature to remove excess solvent. The concentrate (5 ml) was further stored at 50°C to remove any remaining solvent until it reached a dry, paste-like consistency. The amount of the extract in paste form was measured and stored at 4°C until further use.

Determination of the antifungal activity of *S. pulcherrima* plant extract against *C. auris*

The *C. auris* strain National Culture Collection of Pathogenic Fungi (NCCPF) ID: 470097, which is sensitive to fluconazole and amphotericin B, was obtained from NCCPF, Post Graduate Institute of Medical Education and Research, Chandigarh, India. The antifungal activity of *S. pulcherrima* plant extract against *C. auris* was determined using the disc diffusion method. The yeast strains were grown in YPD broth overnight at 150 rpm shaking at 28°C. The overnight culture was then serially diluted to obtain 0.05 OD, and 100 µl of the diluted culture was spread over solidified Sabouraud dextrose agar (SDA). Filter discs containing different concentrations of the methanol and ethyl acetate plant extract were placed

on the SDA plates. The plates were incubated for 48 h at 28°C. After the incubation period, the plates were observed, and the diameters of the zones of inhibition were measured. Fluconazole disc (Himedia, India, 10 µg), ethyl acetate, and methanol were used as controls. Each experiment was performed on three different petri plates with two biological replicates.

Determination of the antioxidant activity of *S. pulcherrima* plant extract

The *in vitro* antioxidant property of the *S. pulcherrima* leaf extract was determined through the 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging assay. For the assay, 0.135 mM DPPH was prepared in methanol (from a stock solution of 100 mM), and the *S. pulcherrima* leaf extract (previously extracted from methanol and ethyl acetate fractions) was prepared in dimethyl sulfoxide (DMSO) with concentrations ranging from 0 to 200 µg/ml. One milliliter of 0.135 mM DPPH and 1 ml of plant extract of varying concentrations were added to test tubes and incubated for 45 min in the dark at room temperature. All experiments were performed in triplicates, and ascorbic acid was used as a standard. Following the incubation, absorbance was measured at 517 nm, and the DPPH scavenging activity was calculated using the following formula:

$$\% \text{ DPPH scavenging activity} = \left\{ \frac{(\text{Abs}_c - \text{Abs}_s)}{\text{Abs}_c} \right\} \times 100$$

where Abs_c is the average absorbance of methanol + DPPH and Abs_s is the average absorbance of sample (different concentrations of plant extract/ascorbic acid) + DPPH.

Determination of total phenolic content of *S. pulcherrima* plant extract

The phenolic contents in the *S. pulcherrima* leaf extract were estimated using the Folin-Ciocalteu reagent. Two hundred microliters of the leaf extract at different concentrations (160 and 320 µg/ml prepared in distilled water) were mixed with 2% sodium carbonate (2 ml) and 10% Folin-Ciocalteu reagent (2.5 ml). The reaction mixture was then incubated at 45°C in a water bath for 20 min. After the incubation, the absorbance was measured at 765 nm. All experiments were performed in triplicate, and gallic acid (Sisco Research Laboratories, India) was used as a standard.

HPTLC detection of phenols in the plant extract

To identify specific phenolic compounds, such as gallic acid and quercetin, in the *S. pulcherrima* extract by Folin-Ciocalteu method, HPTLC analysis was performed at Herbal Health Research Consortium Private Limited in Amritsar, Punjab, India. A silica gel TLC plate coated with fluorescent indicator F₂₅₄ measuring 5.0 × 10.0 cm (Merck, Germany) was used. The ethyl acetate extract of *S. pulcherrima* (2 µl) was applied using the CAMAG Linomat 5 semiautomatic sample application system in the form of bands (6 mm). After developing the TLC plates in a hexane-chloroform-acetic acid (4:5:1 ratio) solvent system, they were air-dried and scanned using a CAMAG TLC scanner at a wavelength of 270 nm with a Deuterium lamp in absorption mode. A gallic acid standard (Sisco Research Laboratories, India) of 1 mg/ml was used for the analysis.

Determination of in vitro antifungal activity of gallic acid against *C. auris*

The antifungal activity of gallic acid was evaluated against six clinical isolates of *C. auris*, which were obtained from NCCPF in Chandigarh, India. The identification numbers of these strains are 470,049, 470,055, 470,097, 470,098, 470,111, and 470,149. All *C. auris* strains used in the study were susceptible to fluconazole and amphotericin B, except of NCCPF 470149, which was resistant to fluconazole. Gallic acid was procured from Sisco Research Laboratories in India, and all experiments were conducted in triplicate.

The antifungal activity of gallic acid against *C. auris* strains was determined using the broth microdilution method based on EUCAST guidelines with modifications (Arendrup et al., 2012). Gallic acid stock solution was diluted in Sabouraud dextrose broth (SDB) to obtain concentrations ranging from 0.06 to 32 mg/ml. Next, 100 µl of the SDB with diluted gallic acid was added to respective wells in 96-well microtiter plates in triplicate, with an inoculum size of 0.5 × 10⁴ CFU/ml. The plates were incubated for 24 h at 35 °C without agitation, and the MIC (50%) was determined by measuring the absorbance at 530 nm, and calculated using the appropriate formula:

$$\text{MIC}(\%) = \left\{ \frac{(\text{Abs}_c - \text{Abs}_s)}{\text{Abs}_c} \right\} \times 100$$

where Abs_c is the absorbance of well-containing media and culture.

The determination of the minimum fungicidal concentration (MFC) of gallic acid against *C. auris* followed the method described by Espinel-Ingroff et al. (2002). From the wells that showed complete inhibition (optically clear microtiter plate wells obtained after treating *C. auris* for the determination of MIC), 20 µl was spread plated on SDA plates and incubated at 35 °C for 48 h. The MFC was determined as the lowest concentration that yielded less than three colonies (Espinel-Ingroff et al., 2002).

Structure prediction: modeling, validation, and superimposition of *C. auris* CA protein

The 3D structure of the *C. auris* CA protein has not yet been solved. The amino acid sequence of the *C. auris* CA protein (269 amino acids) was obtained from the *Candida* genome database (http://www.candidagenome.org/cgi-bin/locus.pl?locus=B9J08_000363), and the 3D structure of the *C. auris* CA protein was modeled using the I-TASSER web interface (Yang et al., 2015). I-TASSER employs a combination of different approaches, including threading, fragment assembly, *ab initio* loop modeling, and structural refinement (Yang et al., 2015). To identify the template protein structure, a BLAST search was conducted against the Protein Data Bank (PDB) database (Berman et al., 2000; McGinnis and Madden, 2004). The top hit obtained was the *C. albicans* CA protein with 79% sequence identity and 77% query coverage. Therefore, the crystal structure of *C. albicans* CA (PDB ID: 6GWU) was used as a primary template to model the *C. auris* CA protein structure. The best structure model was selected based on a confidence score (C-score).

To assess the quality of the modeled structure, we used the Structural Analysis and Verification Server (<http://nihserver.mbi.ucla.edu/SAVES>). Various structure assessment programs were used to analyze the backbone conformations and overall geometric compatibility of interacting residues in the modeled *C. auris* CA protein structure. The Ramachandran plot was used to estimate the phi/psi distributions of the protein backbone. The ERRAT program was used to calculate the nonbonded atomic interactions for the modeled proteins. The compatibility of the 3D atomic model of amino acid with its amino acid sequence (1D) was demonstrated by creating it through the verify-3D program.

To check the structural consistency, we superimposed the modeled structure with the template structure

(6GWU) and calculated root mean square deviation (RMSD) using iPBA server (https://www.dsimb.inserm.fr/dsimb_tools/ipba/example.php). All molecular images were generated through UCSF Chimera software (Pettersen et al. 2004).

Molecular docking

The CA receptor and gallic acid ligand were subjected to molecular docking after energy minimization and refinement of both the modeled and crystal structures. The steepest descent (100 steps) and conjugate gradient (500 steps) algorithms were employed using the Swiss PDB viewer software platform (Guex and Peitsch, 1997). The Spatial Data File (SDF) structure of gallic acid was downloaded from the PubChem (<https://pubchem.ncbi.nlm.nih.gov>) database, with PubChem ID: CID 370. The downloaded SDF structure was converted to PDB format using the online SMILES translator and structure file generator (<https://cactus.nci.nih.gov/translate/>).

Firstly, the zinc metal-ion was docked in the modeled structure of *C. auris* CA protein using the Metal Ion-Binding (MIB) site prediction and docking server (<http://140.128.63.8/MIB/>). Gallic acid was then docked onto the Zn-coordinated *C. auris* CA using the Patchdock web server, with the criteria to generate a maximum of 10 docked poses (Schneidman-Duhovny et al., 2005). The active site amino acids in the *C. auris* CA modeled structure were marked based on the *C. albicans* CA structure (PDB ID: 6GWU). The docked protein–ligand complex was evaluated based on its atomic contact energy (ACE). The interacting residues of *C. auris* CA with the ligand were visualized using UCSF Chimera software (Pettersen et al., 2004).

Results

Determination of the antifungal activity of *S. pulcherrima* plant extract against *C. auris*

The antifungal activity of the methanol and ethyl acetate extracts of *S. pulcherrima* against *C. auris* (NCCPF ID: 470097) was determined using the disc diffusion method. The results showed that both extracts were able to inhibit the growth of *C. auris*, as demonstrated in Figure 1. The zones of inhibition for the methanol extract of *S. pulcherrima* against both *C. albicans* and *C. auris* strains were 11 mm. In contrast, the zones of inhibition




Fig. 1. Antifungal susceptibility assay of *S. pulcherrima* plant extract; A) *C. albicans* and B) *C. auris*; (a) Fluconazole disc, (b) disc with methanol extract of *S. pulcherrima*, and (c) disc with ethyl acetate extract of *S. pulcherrima*

for the ethyl acetate extract of *S. pulcherrima* against *C. albicans* and *C. auris* strains were 10 and 15 mm, respectively. This suggests that the ethyl acetate plant extract has better antifungal activity against *C. auris* than against *C. albicans*. The zones of inhibition for fluconazole against *C. albicans* and *C. auris* were 26 and 24 mm, respectively.

Antioxidant property of *S. pulcherrima* extract

The *S. pulcherrima* leaves extract exhibited antioxidant activity by effectively scavenging the DPPH free radicals. The IC₅₀ values of the extract and ascorbic acid were calculated from the graphs presented in Figure 2A and Figure 2B. The IC₅₀ value of the *S. pulcherrima* leaves extract was found to be 57.16 µg/ml, while the IC₅₀ value of ascorbic acid was 18.61 µg/ml.

Determination of total phenol content of *S. pulcherrima* plant extract

The total phenolic content of the methanol extract of *S. pulcherrima* leaves was determined by constructing a standard curve (Fig. 3) using gallic acid in the x-axis as the standard. The absorbance of the Folin-Ciocalteu reagent-gallic acid mixture at 765 nm was plotted in the y-axis against the concentration of gallic acid. The absorbance values of the *S. pulcherrima* extract for the determination of total phenolic content are provided in Table 1. The results showed that the phenolic content of the 160 µg/ml *S. pulcherrima* extract was equivalent to 40.31 µg/ml gallic acid, while the phenolic content of the 320 µg/ml *S. pulcherrima* extract was equivalent to 79.46 µg/ml gallic acid.




Fig. 2. A) DPPH scavenging activity of *S. pulcherrima* and B) DPPH scavenging activity of ascorbic acid




Fig. 3. Standard graph of gallic acid for determining the total phenol content in *S. pulcherrima* leaf extract

Detection of phenols in the *S. pulcherrima* plant extract

The presence of gallic acid and quercetin in the *S. pulcherrima* plant extract was analyzed by HPTLC. The gallic acid standard had a maximum R_f of 0.43 and a peak area of 16 416.6 (Supplementary Fig. 1A), while the *S. pulcherrima* plant extract showed a peak with a maximum R_f of 0.45 and a peak area of 1 431.3 (Supplementary Fig. 1B). This peak in the plant extract coincided with the peak of the gallic acid standard, indicating the presence of gallic acid in the *S. pulcherrima* plant extract. However, quercetin was not detected in the *S. pulcherrima* plant extract through HPTLC analysis.

Determination of *in vitro* antifungal activity of gallic acid against *C. auris*

The *in vitro* antifungal assay demonstrated that gallic acid was effective in inhibiting the growth of all six strains of *C. auris* used in the study. The minimum in-

hibitory concentration (MIC_{50}) value of gallic acid, which is the lowest concentration that inhibited 50% of the growth of *C. auris* in comparison to untreated *C. auris*, was found to be in the range of 1.6–3.2 mg/ml. The MIC_{50} value of gallic acid (MIC_{50} GA) and MFC = lowest drug concentration that yields three or less colonies of gallic acid against the different *C. auris* strains are presented in Table 2.

Structure modeling and assessment of *C. auris* CA

The I-Tasser webserver was utilized to predict the 3D structure of the *C. auris* CA protein. The input for this analysis was the amino acid sequence of the *C. auris* CA protein in FASTA format. The C-score, a measure of the quality of predicted 3D models of proteins, for the modeled structure of the *C. auris* CA protein was -1.66 (Table 3A). The C-score values for protein models generated by I-Tasser usually range from -5 to 2. A higher C-score implies that the generated model is of higher quality (Yang et al. 2015). The modeled *C. auris* CA protein had a higher C-score, indicating that the predicted model was of good quality.

The quality of the predicted model of the *C. auris* CA protein was further assessed by generating a Ramachandran plot. Analysis of psi/phi angles showed that overall, 96% of residues in the modeled structure were present in the allowed regions of the Ramachandran map. The average ERRAT score of 93.10 for the modeled structure also confirmed the high accuracy of the predicted models. Additionally, the Verify3D software was used to assess the quality of the 3D model of the *C. auris* CA protein. This software assigns a structural class based on

Table 1. The absorbance of *S. pulcherrima* extracts for determination of total phenol content

Concentration [µg/ml]	Absorbance 765 nM	Absorbance 765 nM	Absorbance 765 nM	Mean absorbance
160	0.305	0.303	0.303	0.304
320	0.600	0.624	0.651	0.625

Table 2. Minimum inhibitory concentration of gallic acid

	16	8	1	16	16	Above 64
MIC ₅₀ GA [mg/ml]	1.6	1.6	1.6	3.2	1.6	3.2
MFC GA [mg/ml]	6.4	12.8	12.8	12.8	6.4	12.8

Note: fluconazole resistant strains, MFC stands for minimum fungicidal concentration, GA stands for Gallic acid

Table 3. Molecular modeling studies of *C. auris* CA protein

A – Target-Template details for selected modeled structure							
Protein name	No. of amino acid residues		Templates (PDB ID)			C-score of models	
<i>C. auris</i> CA	269		6GWU			-1.66	
B – Model validation for selected modeled structure							
Protein name	Ramachandran plot statistics					ERRAT statistics	Verify-3D statistics
	residue in a most favorable region	residue in the additional allowed region	residue in the generously allowed region	residue in the disallowed region	number of nonglycine and nonproline residues	score	score
<i>C. auris</i> CA	68.4%	20.7%	7.2%	3.8%	269	93.10	63.94%

its location and environment (alpha, beta, loop, polar, non-polar, etc.) to determine the compatibility of the 3D model of proteins with its amino acid sequence (1D). The Verify3D software provided a 3D–1D score of 63.94% for the protein model, indicating that 63.94% of the amino acid residues of the *C. auris* CA protein are compatible with its 3D model (Table 3B).

Therefore, all three assessment methods, PROCHECK, ERRAT, and Verify3D, confirmed the reliability of the predicted 3D structures. Superimposition of the modeled CA protein structure of *C. auris* and the experimentally determined CA structure of *C. albicans* showed an RMSD value (RMSD gives the average deviation between the corresponding atoms of two proteins and the lower RMSD value suggests the higher structural similarity between proteins) of 0.43 Å (Supple-

mentary Fig. 2), further confirming the high accuracy of the modeled structure.

Molecular docking and evaluation of interacting residues

MIB web server predicted the binding residues i.e., for the positions 94 Cys, 149 His, and 152 Cys where the Zn²⁺ metal ion can bind in the *C. auris* CA protein. When the modeled structure of CA of *C. auris* was docked with Zn²⁺ metal ion, we found that all active site residues i.e., 94C, 149H, and 152C were interacting with it. The interacting residues are listed in (Table 4). The docking score and ACE which were obtained after docking the *C. auris* CA protein with gallic acid were 219 and -12.24 kcal/mol, respectively (Table 5). We also evaluated the docked complexes of both the CA proteins of *C. auris*

Table 4. Interacting residues and secondary structure pattern of *C. auris* and *C. albicans* CA protein within 5 Å from the Zn²⁺ metal ion

<i>C. albicans</i>		<i>C. auris</i> (+18 of <i>C. albicans</i> residues)	
within 5 Å zinc ion and secondary structure (sec. str) analysis			
amino acid and position	sec. str	amino acid and position	sec. str
76 CYS	strand	94 CYS	coil
131 HIS	strand	149 HIS	coil
134 CYS	coil	152 CYS	coil
78 ASP	coil	96 ASP	coil
135 GLY	helix	153 GLY	coil
100 ALA	helix	118 ALA	coil
101 ASN	helix	–	–
136 GLY	helix	–	–
–	–	155 VAL	helix
–	–	95 SER	coil

Table 5. Docking studies of CA of *C. auris* and *C. albicans* yeast protein with gallic acid

Protein	Ligand	Atomic contact energy [kcal/mol]	Docking score
CA of <i>C. albicans</i>	gallic acid	–71.85	1850
CA of <i>C. auris</i> *		–12.24	219

and *C. albicans* with gallic acid using Chimera software (all within 5 Å from the ligand) and found significant changes in the binding residues and the neighboring residues (Table 6).

The MIB web server predicted the binding residues for the positions 94 Cys, 149 His, and 152 Cys, where the Zn²⁺ metal ion can bind in the *C. auris* CA protein. Docking the modeled structure of CA of *C. auris* with Zn²⁺ metal ion revealed that all active site residues (94C, 149H, and 152C) were interacting with it. The interacting residues are listed in (Table 4).

When the *C. auris* CA protein was docked with gallic acid, the docking score and ACE were 219 and –12.24 kcal/mol, respectively (Table 5). We evaluated the docked complexes of both the CA proteins of *C. auris* and *C. albicans* with gallic acid using Chimera software and found significant changes in the binding residues and the neighboring residues (Table 6). All residues within 5 Å from the ligand were analyzed.

When comparing the docking of gallic acid with the CA protein of *C. albicans* and *C. auris*, we found that the binding of gallic acid with *C. albicans* CA protein was energetically

more favorable than with *C. auris* CA protein. The ACE for docking gallic acid with *C. albicans* CA protein was –71.85 kcal/mol, whereas the ACE for docking gallic acid with *C. auris* CA protein was –12.24 kcal/mol. The fact that the ACE was higher for *C. auris* CA protein suggests that the binding of gallic acid with *C. albicans* CA protein was more energetically favorable. Lower ACE indicates a more energetically favorable binding. However, in the docked complex of gallic acid with *C. auris* CA protein, all three desired active site residues (compared to active sites of *C. albicans* CA) did not interact with the ligand. Instead, only two active site residues (149H and 152C) were present in the docked complex. In contrast, when *C. albicans* CA was docked with gallic acid, we found interactions with all three desired active site residues. These observations indicate the presence of structural and mutational changes in the CA of *C. auris*.

To verify this hypothesis, we analyzed the secondary structure distributions of all the interacting residues of both docked complexes with gallic acid (all within 5 Å from the ligand). We found a significant change in se-

Table 6. Interacting residues and secondary structure pattern of CA of *C. auris* and *C. albicans* yeast protein within 5 Å from the gallic acid

<i>C. albicans</i>		<i>C. auris</i> (+18 of <i>C. albicans</i> residues)	
within 5 Å gallic acid and secondary structure (sec. str) analysis			
amino acid and position	sec. str	amino acid and position	sec. str
76 CYS	strand	–	–
131 HIS	strand	149 HIS	coil
134 CYS	coil	152 CYS	coil
133 ASP	coil	151 ASP	coil
80 ARG	coil	98 ARG	coil
79 SER	coil	97 SER	coil
78 ASP	coil	96 ASP	coil
77 SER	coil	–	–
137 ILE	helix	–	–
136 GLY	helix	–	–
100 ALA	helix	–	–
99 ILE	helix	–	–
135 GLY	helix	153 GLY	coil
–	–	150 THR	coil
–	–	236 VAL	coil
–	–	36 LYS	coil
–	–	38 GLN	helix




Fig. 4. A) Interacting residues and secondary structure (Helix: Orange, Coil: Green, and Strand: Blue) pattern of *C. albicans* CA protein within 5 Å from the ligand (gallic acid); B) Interacting residues and secondary structure (Helix: Orange, Coil: Green, and Strand: Blue) pattern of *C. auris* CA protein within 5 Å from the ligand (gallic acid)

condary structure in both docked structures (Fig. 4A and Fig. 4B). In the crystal structure of CA (PDB ID: 6GWU) of *C. albicans*, it has been reported that the active site residues (Ile 99, Gly 135, Phe 116, and Leu 121) create a narrow tunnel, which serves as the point of entry to the positively charged active site. The analysis of the modeled

structure of *C. auris* CA protein showed that the Ile 117, Gly 153, Phe 134, and Leu 139 residues of *C. auris* CA protein also created a narrow tunnel. In *C. albicans* CA protein, there is a distinct salt bridge made up of residues present between arginine at position 80 and aspartic acid at position 133 (Arg80–Asp133) that contributes to the

formation of the active site cavity (Dostál et al. 2018). The salt bridge regulates the tunnel's shape and openness and contributes to the formation of the active site cavity in *C. albicans* CA protein (Dostál et al. 2018). A similar salt bridge was also present in the *C. auris* CA protein (Arg 98–Asp 151), but four positions had mutations (shown as double asterisk marks) (Supplementary Fig. 3). We infer that these mutations hinder the accessibility of gallic acid to the active site of *C. auris* CA protein, thereby decreasing the strength of binding.

Discussion

C. auris infections present a severe global public health threat due to their high mortality rate, rapid transmission, and multidrug resistance (Chowdhary et al., 2017; Giarratano et al. 2018). Since its first identification in 2009, *C. auris* infections have caused hospital outbreaks in over thirty countries on six continents (Rhodes and Fisher, 2019). Besides multidrug-resistant strains, different *C. auris* strains exhibit pan-resistance, which is resistance to all three major classes of antifungal drugs: azole, echinocandins, and polyene (O'Brien et al., 2020; Ostrowsky et al., 2020). Furthermore, the side effects and low bioavailability of existing antifungals (Thammahong et al., 2017; Akhtar et al., 2021) can further hinder the treatment of *C. auris* infections. Therefore, it is necessary to continue searching for new, effective, and safe antifungal drugs. Plants can be an essential source of novel drugs for treating various ailments. Humans have been using plants and plant-based compounds as part of various traditional medicinal practices, such as traditional Chinese medicine, Unani medicine, Iranian traditional medicine, Siddha medicine, Kampo medicine, and Ayurveda (Akhtar et al., 2021). Plants are rich in a plethora of metabolites belonging to different classes such as alkaloids, flavonoids, phenolic acids, and saponins (Akhtar et al., 2021). More than 50 000 secondary metabolites have been discovered in various plants, and modern medicine relies on these metabolites (Teoh, 2016). Several metabolites found in plants, such as saponins, flavonoids, polyphenols, terpenoids, tannins, alkaloids, and coumarins, have been reported to possess antifungal properties (Castillo et al., 2012; Mishra et al., 2020; Akhtar et al., 2021). In this study, we evaluated the antifungal property of *S. pulcherrima* leaves' extract against *C. auris*, identified the active

compound responsible for the antifungal property, and determined the potential mode of action of the active compound by *in silico* approach.

Previous studies have reported the antioxidant and antifungal properties of *S. pulcherrima* methanolic extract against *C. albicans* (Paul et al., 2010; Mazumder et al., 2012; Mazumder et al., 2014). However, the modes of action and efficacy of the extract against multi-drug *Candida* spp. were not explored. In our study, both the methanol and ethyl acetate extract exhibited antioxidant and antifungal properties against *C. auris* and *C. albicans*. After determining the antifungal and antioxidant properties of the plant extract, we conducted experiments to identify the potential active metabolite in the extract.

Previously, aerial parts of *S. pulcherrima* were found to contain two triterpenoids, tormentic acid, and 23-hydroxycorosolic acid (Ghosh et al., 2020), which inhibited biofilm formation by *Pseudomonas aeruginosa* (Ghosh et al., 2020). Given the presence of phenolic compounds with antioxidant properties in the plant extract, we performed an HPTLC experiment to identify potential antioxidant compounds, such as quercetin and gallic acid. The HPTLC analysis confirmed the presence of gallic acid in the extract. Gallic acid is a phenolic compound naturally found in various herbal plants and fruits, such as *Camellia sinensis*, *Oenothera biennis*, *Vitis vinifera*, *Terminalia bellerica*, and *Terminalia chebula* (Karamać et al., 2006; Genwali et al., 2013; Singh et al., 2019). Gallic acid has been reported in *in vitro* and *in vivo* studies to possess various therapeutic potentials, including antimicrobial, antioxidant, anti-inflammatory, anticancer (Choi et al., 2009; Giftson et al., 2010a; Shao et al., 2015; Kahkeshani et al., 2019; Yang et al., 2020), chondroprotective, hepatoprotective, neuroprotective, and antidiabetic properties (Kroes et al., 1992; Giftson et al., 2010b; Patel and Goyal, 2011; Huang et al., 2012; Nabavi et al., 2012; Gandhi et al., 2014; Bayramoglu et al., 2015; Wen et al., 2015).

An FDA-unapproved homeopathic drug manufactured by BioActive Nutritional, Florida, USA, with gallic acid as the active ingredient, has been marketed for temporary relief from itching, back pain, joint pain, nasal congestion, fatigue, allergic rhinitis, and dyspepsia (DailyMed, 2013). However, the safety and efficacy of this homeopathic drug have not been evaluated by the FDA (DailyMed, 2013) *in vitro* studies have reported the antifungal activity of gallic acid against different hu-

man fungal pathogens, such as *C. albicans*, *Candida krusei*, *Candida glabrata*, *Candida tropicalis*, *Microsporum canis*, and *Trichophyton* species (Li et al., 2017; Carvalho et al., 2018). In a study conducted by Li et al. (2017), the MIC of gallic acid against *C. glabrata*, *C. albicans*, and *C. tropicalis* was reported to be between 12 and 100 µg/ml. Similarly, another study reported that the MIC of the gallic acid against *C. albicans*, *C. krusei*, *C. tropicalis*, and *C. glabrata* as well as dermatophytes such as *M. canis* and *Trichophyton* species, ranged between 0.25 and 1 mg/ml (Carvalho et al., 2018). In our study, gallic acid exhibited antifungal activity against *C. auris*, with a MIC ranging from 1.6 to 3.2 mg/ml, with four strains having a MIC of 1.6 mg/ml and the remaining two *C. auris* strains having a MIC of 3.2 mg/ml. This is consistent with previous studies that reported the antifungal activity of gallic acid against different human fungal pathogens such as *C. albicans*, *C. glabrata*, *C. krusei*, and *C. tropicalis*, as well as dermatophytes such as *M. canis* and *Trichophyton* species (Li et al., 2017; Carvalho et al., 2018). Furthermore, the administration of gallic acid to immunocompromised mice models with systemic *C. albicans* infection has been reported to reduce mortality rate, inflammation, and fungal load in liver tissues of mice, corroborating the hypothesis that gallic acid is one of the potential active compounds in *S. pulcherrima* responsible for its antifungal property (Li et al., 2017).

We conducted *in silico* experiments to investigate the potential mode of action of gallic acid. Prior studies have reported that the inhibition of ergosterol biosynthesis and reduction in CYP51 enzyme activity are the mechanisms behind the antifungal activity of gallic acid (Li et al., 2017; Carvalho et al., 2018). In our study, we explored the CA protein of *C. auris* as a potential target of gallic acid, which is responsible for virulence and various other important biological functions in different fungi (Schlicker et al., 2009; Elleuche and Pöggeler, 2010; Supuran and Capasso, 2021). Targeting virulence proteins could minimize the adverse effects on host cells and limit the emergence of drug resistance in microbes by reducing the selective pressure (Marra, 2004; Heras et al., 2015). Therefore, CA can be a promising target for discovering novel antifungal drugs.

In a previous study, the repurposing of FDA-approved CA inhibitors such as ethoxzolamide, acetazolamide, and

methazolamide, which were used to treat glaucoma or duodenal ulcers, demonstrated antibacterial activity against Vancomycin-resistant *Enterococcus faecalis* and *Enterococcus faecium* (Kaur et al., 2020). The molecular docking and molecular dynamics study indicated that the CA of *E. faecium* could be the intracellular target of ethoxzolamide, acetazolamide, and methazolamide (Kaur et al., 2020).

Our study suggests that gallic acid can bind with the active site residues of CA proteins from *C. auris* and *C. albicans*. The majority of the active site residues are hydrophobic (Ile 99, Gly 135, Phe 116, and Leu 121), forming a narrow tunnel that serves as the point of entry to the positively charged active site in a *C. albicans* crystal structure (6GWU). In the simulated structure of *C. auris*, we found that these residues (Ile 117, Gly 153, Phe 134, and Leu 139) were present in the protein as well, forming a small tunnel. The distinct salt bridges of 54 residues (Arg80–Asp133) that contribute to the formation of the active site cavity in *C. albicans* and regulate the shape and openness of the tunnel were also present in *C. auris* (Arg98–Asp151). However, at four positions, mutations were found in *C. auris* CA protein (Supplementary Fig. 3). The residues Asp 83, Val 95, Ile 118, and Lys 124 of *C. albicans* CA protein were mutated to Glu 101, Thr 113, Val 136, and Arg 142, respectively, in *C. auris* CA protein. We believe that these changes make gallic acid less accessible to the active site, lowering the binding strength. Future studies can focus on developing derivatives of gallic acid that can target the CA of *C. auris* more efficiently, leading to the development of novel antifungal drugs with new modes of action.

Conclusion

The antifungal analysis conducted in this study suggests that *S. pulcherrima*, also known as Mesaki, could serve as a potential source of novel antifungal drugs, with gallic acid being one of the active molecules responsible for its antifungal properties. The MIC of gallic acid against *C. auris* ranged from 1.6 to 3.2 mg/ml. Our *in silico* experiments revealed that gallic acid could bind to the CA protein, which is essential for fungal virulence in *C. auris* and *C. albicans*. Moreover, for the first time, we predicted the structure of the CA protein from *C. auris*. Our research showed that gallic acid from Mesaki tree leaves could potentially combat fluconazole-resistant

C. auris clinical isolates. However, further *in vivo* and clinical studies are required to confirm gallic acid's antifungal properties. In the future, derivatives of gallic acid with enhanced antifungal potential targeting the CA protein could be developed, leading to the emergence of a new class of antifungal medications that target the CA protein.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Authors' contributions

NA: Investigation, methodology, formal analysis, writing – original draft, and writing – review and editing; DP: investigation, methodology, formal analysis, and writing – original draft; AS: investigation and formal analysis; MK: investigation, methodology, formal analysis, and writing – original draft; AG: supervision, validation, and writing – review and editing; MAM: conceptualization, visualization, formal analysis, supervision, writing – original draft, and writing – review and editing.

Ethics approval

Not applicable.

Acknowledgments

MAM would like to acknowledge the Science and Engineering Research Board, India for providing lab funding through the core research grant (EMR/2017/002299) under sanction order SERB/F/10997/2018–2019.

References

- Abdolrasouli A., Armstrong-James D., Ryan L., Schelenz, S. (2017) *In vitro* efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with *Candida auris*. *Mycoses* 60: 758–763. <https://doi.org/10.1111/myc.12699>
- Adams E., Quinn M., Tsay S., Poirot E., Chaturvedi S., Southwick K., Greenko J., Fernandez R., Kallen A., Vallabhaneni S., et al. (2018) *Candida auris* in healthcare facilities, New York, USA, 2013–2017. *Emerg. Infect. Dis.* 24: 1816–1824. <https://doi.org/10.3201/eid2410.180649>
- Ademe M., Girma F. (2020) *Candida auris*: from multidrug resistance to pan-resistant strains. *Infect. Drug Resist.* 13: 1287–1294. <https://doi.org/10.2147/IDR.S249864>
- Akhtar N., Ayoubi R., Kour V., Goutam U., Mannan M.A. (2021) *Natural products, for fungal diseases management and prevention*. *Nat. Prod. J.* 11: e110521193310. <https://doi.org/10.2174/2210315511666210512035847>
- Akhtar N., Choudhury N., Kumar N. (2017a) *Evaluation of antioxidant and antimicrobial potentials of Ecliptaprostrata collected from the Nepal region*. *Pharma Innov.* 6: 4–7.
- Akhtar N., Choudhury N., Kumar N. (2017b) *Antioxidant and antimicrobial potentials of Artemisia indica collected from the Nepal region*. *J. Pharm. Sci. Res.* 9: 1822–1826.
- Arendrup M.C., Cuenca-Estrella M., Lass-Flörl C., Hope W. EUCAST-AFST (2012) *EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*. *Clin. Microbiol. Infect.* 18: E246–247. <https://doi.org/10.1111/j.1469-0691.2012.03880.x>
- Bayramoglu G., Kurt H., Bayramoglu A., Gunes H.V., Degirmenci İ., Colak S. (2015) *Preventive role of gallic acid on hepatic ischemia and reperfusion injury in rats*. *Cyto-technology* 67: 845–849. <https://doi.org/10.1007/s10616-014-9724-1>
- Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) *The Protein Data Bank*. *Nucl. Acids Res.* 28: 235–242. <https://doi.org/10.1093/nar/28.1.235>
- Bidaud A.L., Djenontin E., Botterel F., Chowdhary A., Dannaoui E. (2020) *Colistin interacts synergistically with echinocandins against Candida auris*. *Int. J. Antimicrob. Agents* 55: 105901. <https://doi.org/10.1016/j.ijantimicag.2020.105901>
- Buck J., Levin L.R. (2011) *Physiological sensing of carbon dioxide/bicarbonate/pH via cyclic nucleotide signaling*. *Sensors* 11: 2112–2128. <https://doi.org/10.3390/s110202112>
- Cândido E. de S., Affonseca F., Cardoso M.H., Franco O.L. (2020) *Echinocandins as biotechnological tools for treating Candida auris infections*. *J. Fungi* 6: 185. <https://doi.org/10.3390/jof6030185>
- Carvalho R.S., Carollo C.A., Magalhães J.C., Palumbo J.M.C., Boaretto A.G., Sá I.C.N., Ferraz A.C., Lima W.G., Siqueira J.M., Ferreira J.M.S. (2018) *Antibacterial and antifungal activities of phenolic compound-enriched ethyl acetate fraction from Cochlospermum regium (mart. Et. Schr.) Pilger roots: Mechanisms of action and synergism with tannin and gallic acid*. *South Afr. J. Bot.* 114: 181–187. <https://doi.org/10.1016/j.sajb.2017.11.010>
- Chen J., Tian S., Han X., Chu Y., Wang Q., Zhou B., Shang H. (2020) *Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris*. *BMC Infect. Dis.* 20: 827. <https://doi.org/10.1186/s12879-020-05543-0>
- Choudhury N., Akhtar N., Kumar N. (2017) *Study on methanolic extract of Ageratum conyzoides for its ability to act as an antioxidant and to suppress the microbial growth*. *Pharma Innov.* 6: 170–173.
- Chow N.A., De Groot T., Badali H., Abastabar M., Chiller T.M., Meis J.F. (2019) *Potential fifth clade of Candida auris, Iran, 2018*. *Emerg. Infect. Dis.* 25: 1780–1781. <https://doi.org/10.3201/eid2509.190686>
- Chowdhary A., Sharma C., Meis J.F. (2017) *Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally*. *PLoS Pathog.* 13: e1006290. <https://doi.org/10.1371/journal.ppat.1006290>
- Chybowska A.D., Childers D.S., Farrer R.A. (2020) *Nine things genomics can tell us about Candida auris*. *Front. Genet.* 11: 351. <https://doi.org/10.3389/fgene.2020.00351>
- Cummins E.P., Selfridge A.C., Sporn P.H., Sznajder J.J., Taylor C.T. (2014) *Carbon dioxide-sensing in organisms and its implications for human disease*. *Cell. Mol. Life Sci.* 71: 831–845. <https://doi.org/10.1007/s00018-013-1470-6>

- DailyMed (2013) *Gallicacid- Gallicumacidum liquid*. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80f60b1-1e1b-432b-bb89-d7ada1d0b811> (accessed 9.24.21).
- Dostál J., Blaha J., Hadravová R., Hubálek M., Heidingsfeld O., Pichová I. (2020) *Cellular localization of carbonic anhydrase Nce103p in Candida albicans and Candida parapsilosis*. *Int. J. Mol. Sci.* 21: 850. <https://doi.org/10.3390/ijms21030850>
- Du H., Bing J., Hu T., Ennis C.L., Nobile C.J., Huang G. (2020) *Candida auris: Epidemiology, biology, antifungal resistance, and virulence*. *PLoS Pathog.* 16: e1008921. <https://doi.org/10.1371/journal.ppat.1008921>
- Eldesouky H.E., Li X., Abutaleb N.S., Mohammad H., Seleem M.N. (2018) *Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris*. *Int. J. Antimicrob. Agents* 52: 754–761. <https://doi.org/10.1016/j.ijantimicag.2018.08.016>
- Elleuche S., Pöggeler S. (2010) *Carbonic anhydrases in fungi*. *Microbiol. Read. Engl.* 156: 23–29. <https://doi.org/10.1099/mic.0.032581-0>
- El-Nagar A., Elzaawely A.A., Taha N.A., Nehela Y. (2020) *The antifungal activity of Gallic acid and its derivatives against Alternaria solani, the causal agent of tomato early blight*. *Agronomy* 10: 1402. <https://doi.org/10.3390/agronomy10091402>
- Fasciana T., Cortegiani A., Ippolito M., Giarratano A., Di Quattro O., Lipari D., Graceffa D., Giammanco A. (2020) *Candida auris: an overview of how to screen, detect, test and control this emerging pathogen*. *Antibiotics* 9: E778. <https://doi.org/10.3390/antibiotics9110778>
- Forsberg K., Woodworth K., Walters M., Berkow E.L., Jackson B., Chiller T., Vallabhaneni S. (2019) *Candida auris: the recent emergence of a multidrug-resistant fungal pathogen*. *Med. Mycol.* 57: 1–12. <https://doi.org/10.1093/mmy/my054>
- Gandhi G.R., Jothi G., Antony P.J., Balakrishna K., Paulraj M.G., Ignacimuthu S., Stalin A., Al-Dhabi N.A. (2014) *Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPAR γ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway*. *Eur. J. Pharmacol.* 745: 201–216. <https://doi.org/10.1016/j.ejphar.2014.10.044>
- Ghannoum M., Arendrup M.C., Chaturvedi V.P., Lockhart S.R., McCormick T.S., Chaturvedi S., Berkow E.L., Juneja D., Tarai B., Azie N. et al. (2020) *Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections*. *Antibiotics* 9: E539. <https://doi.org/10.3390/antibiotics9090539>
- Ghosh C., Bhowmik J., Ghosh R., Das M.C., Sandhu P., Kumari M., Acharjee S., Daware A.V., Akhter Y., Banerjee B. et al. (2020) *The anti-biofilm potential of triterpenoids isolated from Sarcochlamys pulcherrima (Roxb.) Gaud.* *Microb. Pathog.* 139: 103901. <https://doi.org/10.1016/j.micpath.2019.103901>
- Giarratano A., Giammanco A., Chowdhary A., Cortegiani A., Fasciana T., Misseri G. (2018) *Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris*. *J. Intensive Care* 6: 69. <https://doi.org/10.1186/s40560-018-0342-4>
- Giftson J.S., Jayanthi S., Nalini N. (2010) *Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1,2-dimethylhydrazine induced rat colon carcinogenesis*. *Invest. New Drugs* 28: 251–259. <https://doi.org/10.1007/s10637-009-9241-9>
- Gintjee T.J., Donnelley M.A., Thompson G.R. (2020) *Aspiring antifungals: review of current antifungal pipeline developments*. *J. Fungi* 6: E28. <https://doi.org/10.3390/jof6010028>
- Guex N., Peitsch M.C. (1997) *SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling*. *Electrophoresis* 18: 2714–2723. <https://doi.org/10.1002/elps.1150181505>
- Hall R.A., Sordi L.D., MacCallum D.M., Topal H., Eaton R., Bloor J.W., Robinson G.K., Levin L.R., Buck J., Wang Y. et al. (2010) *CO₂ Acts as a signalling molecule in populations of the fungal pathogen candida albicans*. *PLoS Pathog.* 6: 1001193. <https://doi.org/10.1371/journal.ppat.1001193>
- Heras B., Scanlon M.J., Martin J.L. (2015) *Targeting virulence not viability in the search for future antibacterials*. *Br. J. Clin. Pharmacol.* 79: 208–215. <https://doi.org/10.1111/bcp.12356>
- Huang G. (2012) *Regulation of phenotypic transitions in the fungal pathogen Candida albicans*. *Virulence* 3: 251–261. <https://doi.org/10.4161/viru.20010>
- Huang P.J., Hseu Y.C., Lee M.S., Senthil Kumar K.J., Wu C.R., Hsu L.S., Liao J.W., Cheng I.S., Kuo Y.T., Huang S.Y., et al. (2012) *In vitro and in vivo activity of gallic acid and Toona sinensis leaf extracts against HL-60 human promyelocytic leukemia*. *Food Chem. Toxicol.* 50: 3489–3497. <https://doi.org/10.1016/j.fct.2012.06.046>
- Iyer K.R., Whitesell L., Porco J.A., Henkel T., Brown L.E., Robbins N., Cowen L.E. (2020) *Translation inhibition by rocaglates activates a species-specific cell death program in the emerging fungal pathogen Candida auris*. *mBio* 11: e03329-19. <https://doi.org/10.1128/mBio.03329-19>
- Jungbluth M., Mösch H.U., Taxis C. (2012) *Acetate regulation of spore formation is under the control of the ras/cyclic AMP/protein kinase a pathway and carbon dioxide in Saccharomyces cerevisiae*. *Eukaryot. Cell* 11: 1021–1032. <https://doi.org/10.1128/EC.05240-11>
- Kahkeshani N., Farzaei F., Fotouhi M., Alavi S.S., Bahramsoltani R., Naseri R., Momtaz S., Abbasabadi Z., Rahimi R., Farzaei M.H. et al. (2019) *Pharmacological effects of gallic acid in health and diseases: a mechanistic review*. *Iran. J. Basic Med. Sci.* 22: 225–237. <https://doi.org/10.22038/ijbms.2019.32806.7897>
- Kaur J., Cao X., Abutaleb N.S., Elkashif A., Graboski A.L., Krabill A.D., AbdelKhalek A.H., An W., Bhardwaj A., Seleem M.N. et al. (2020) *Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant Enterococcus*. *J. Med. Chem.* 63: 9540–9562. <https://doi.org/10.1021/acs.jmedchem.0c00734>

- Kroes B.H., van den Berg A.J., Quarles van Ufford H.C., van Dijk H., Labadie R.P. (1992) *Anti-inflammatory activity of gallic acid*. *Planta Med.* 58: 499–504. <https://doi.org/10.1055/s-2006-961535>
- Lamoth F., Kontoyiannis D.P. (2018) *The Candida auris alert: facts and perspectives*. *J. Infect. Dis.* 217: 516–520. <https://doi.org/10.1093/infdis/jix597>
- Li Z.J., Liu M., Dawuti G., Dou Q., Ma Y., Liu H.G., Aibai S. (2017) *Antifungal activity of gallic acid in vitro and in vivo*. *Phytother. Res.* 31: 1039–1045. <https://doi.org/10.1002/ptr.5823>
- Lockhart S.R., Etienne K.A., Vallabhaneni S., Farooqi J., Chowdhary A., Govender N.P., Colombo A.L., Calvo B., Cuomo C.A., Desjardins C.A. et al. (2017) *Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses*. *Clin. Infect. Dis.* 64: 134–140. <https://doi.org/10.1093/cid/ciw691>
- Marra A. (2004) *Can virulence factors be viable antibacterial targets?* *Expert Rev. Anti Infect. Ther.* 2: 61–72. <https://doi.org/10.1586/14787210.2.1.61>
- Matsumoto M., Ishida K., Konagai A., Maebashi K., Asaoka T. (2002) *Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi*. *Antimicrob. Agents Chemother.* 46: 308–314. <https://doi.org/10.1128/AAC.46.2.308-314.2002>
- Mazumder A.H., Das J., Gogoi H.K., Chattopadhyay P., Paul S.B. (2014) *Antimicrobial activity of methanol extract and fractions from Sarcochlamys pulcherrima*. *Bangladesh J. Pharmacol.* 9: 4–9. <https://doi.org/10.3329/bjp.v9i1.16760>
- Mazumder A.H., Das J., Gogoi H.K., Paul S.B. (2015) *Pharmaceutical scope of a phytochemically unexplored medicinal plant, Sarcochlamys pulcherrima (Roxb.) Gaud.: a review*. *Pharmacogn. Rev.* 9: 81–83. <https://doi.org/10.4103/0973-7847.156358>
- Mazumder A.H., Das J., Kumar Gogoi H., Chattopadhyay P., Singh L., Paul S.B. (2012) *In vitro activity of some medicinal plants from Cachar district, Assam (India) against Candida albicans*. *Pharmacogn. J.* 4: 35–39. <https://doi.org/10.5530/pj.2012.33.6>
- McGinnis S., Madden T.L. (2004) *BLAST: at the core of a powerful and diverse set of sequence analysis tools*. *Nucl. Acids Res.* 32: W20–W25. <https://doi.org/10.1093/nar/gkh435>
- Nabavi S.F., Habtemariam S., Jafari M., Sureda A., Nabavi S.M. (2012) *Protective role of gallic acid on sodium fluoride induced oxidative stress in rat brain*. *Bull. Environ. Contam. Toxicol.* 89: 73–77. <https://doi.org/10.1007/s00128-012-0645-4>
- O'Brien B., Liang J., Chaturvedi S., Jacobs J.L., Chaturvedi V. (2020) *Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations*. *Lancet Microbe* 1: e193–e194. [https://doi.org/10.1016/S2666-5247\(20\)30090-2](https://doi.org/10.1016/S2666-5247(20)30090-2)
- Oliver J.D., Sibley G.E.M., Beckmann N., Dobb K.S., Slater M.J., McEntee L., du Pré S., Livermore J., Bromley M.J., Wiederhold N.P. et al. (2016) *F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase*. *Proc. Natl. Acad. Sci. USA* 113: 12809–12814. <https://doi.org/10.1073/pnas.1608304113>
- Ostrowsky B., Greenko J., Adams E., Quinn M., O'Brien B., Chaturvedi V., Berkow E., Vallabhaneni S., Forsberg K., Chaturvedi S. et al. (2020) *Candida auris isolates resistant to three classes of antifungal medications – New York, 2019*. *Morb. Mortal. Wkly. Rep.* 69: 6–9. <https://doi.org/10.15585/mmwr.mm6901a2>
- Patel S.S., Goyal R.K. (2011) *Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats*. *Pharmacogn. Res.* 3: 239–245. <https://doi.org/10.4103/0974-8490.89743>
- Paul S.B., Mazumder A.H., Gogoi H.K., Gogoi B.J., Chaurasia A., Singh L., Srivastava R.B. (2010) *Evaluation of in vitro antioxidant activity of some plants of Cachar district, Assam*. *Pharmacogn. J.* 2: 289–292. [https://doi.org/10.1016/S0975-3575\(10\)80118-X](https://doi.org/10.1016/S0975-3575(10)80118-X)
- Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. (2004) *UCSF Chimera – a visualization system for exploratory research and analysis*. *J. Comput. Chem.* 25: 1605–1612. <https://doi.org/10.1002/jcc.20084>
- Rhodes J., Fisher M.C. (2019) *Global epidemiology of emerging Candida auris*. *Curr. Opin. Microbiol.* 52: 84–89. <https://doi.org/10.1016/j.mib.2019.05.008>
- Rudramurthy S.M., Chakrabarti A., Paul R.A., Sood P., Kaur H., Capoor M.R., Kindo A.J., Marak R.S.K., Arora A., Sardana R. et al. (2017) *Candida auris candidaemia in Indian ICUs: Analysis of risk factors*. *J. Antimicrob. Chemother.* 72: 1794–1801. <https://doi.org/10.1093/jac/dkx034>
- Ruiz-Gaitán A., Moret A.M., Tasiás-Pitarch M., Aleixandre-López A.I., Martínez-Morel H., Calabuig E., Salavert-Lletí M., Ramírez P., López-Hontangas J.L., Hagen F. et al. (2018) *An outbreak due to Candida auris with prolonged colonization and candidaemia in a tertiary care European hospital*. *Mycoses* 61: 498–505. <https://doi.org/10.1111/myc.12781>
- Sathyapalan D.T., Antony R., Nampoothiri V., Kumar A., Shashindran N., James J., Thomas J., Prasanna P., Sudhir A.S., Philip J.M. et al. (2021) *Evaluating the measures taken to contain a Candida auris outbreak in a tertiary care hospital in South India: an outbreak investigational study*. *BMC Infect. Dis.* 21: 425. <https://doi.org/10.1186/s12879-021-06131-6>
- Schlicker C., Hall R.A., Vullo D., Middelhaufe S., Gertz M., Supuran C.T., Mühlischlegel F.A., Steegborn C. (2009) *Structure and inhibition of the CO₂-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans*. *J. Mol. Biol.* 385: 1207–1220. <https://doi.org/10.1016/j.jmb.2008.11.037>
- Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. (2005) *PatchDock and SymmDock: servers for rigid and symmetric docking*. *Nucl. Acids Res.* 33: W363–W367. <https://doi.org/10.1093/nar/gki481>

- Shaban S., Patel M., Ahmad A., (2020) *Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris*. Sci. Rep. 10: 1162. <https://doi.org/10.1038/s41598-020-58203-3>
- Simonetti G., Brasili E., Pasqua G. (2020) *Antifungal activity of phenolic and polyphenolic compounds from different matrices of Vitis vinifera L. against human pathogens*. Molecules 25: E3748. <https://doi.org/10.3390/molecules25163748>
- Srinivasan A., Lopez-Ribot J.L., Ramasubramanian A.K. (2014) *Overcoming antifungal resistance*. Drug Discov. Today Technol. 11: 65–71. <https://doi.org/10.1016/j.ddtec.2014.02.005>
- Sumiyoshi M., Miyazaki T., Makau J.N., Mizuta S., Tanaka Y., Ishikawa T., Makimura K., Hirayama T., Takazono T., Saijo T. et al. (2020) *Novel and potent antimicrobial effects of caspofungin on drug-resistant Candida and bacteria*. Sci. Rep. 10: 17745. <https://doi.org/10.1038/s41598-020-74749-8>
- Supuran C.T., Capasso C. (2021) *A highlight on the inhibition of fungal carbonic anhydrases as drug targets for the antifungal armamentarium*. Int. J. Mol. Sci. 22: 4324. <https://doi.org/10.3390/ijms22094324>
- Teoh E.S. (2016) *Secondary metabolites of plants*. [in:] *Medicinal orchids of Asia*. Ed. Teoh E.S. Springer International Publishing: 59–73. https://doi.org/10.1007/978-3-319-24274-3_5
- Thammahong A., Puttikamonkul S., Perfect J.R., Brennan R.G., Cramer R.A. (2017) *Central role of the trehalose biosynthesis pathway in the pathogenesis of human fungal infections: opportunities and challenges for therapeutic development*. Microbiol. Mol. Biol. Rev. 81: e00053-16. <https://doi.org/10.1128/MMBR.00053-16>
- Wen L., Qu T.B., Zhai K., Ding J., Hai Y., Zhou J.L. (2015) *Gallic acid can play a chondroprotective role against AGE-induced osteoarthritis progression*. J. Orthop. Sci. 20: 734–741. <https://doi.org/10.1007/s00776-015-0718-4>
- Yang J., Yan R., Roy A., Xu D., Poisson J., Zhang Y. (2015) *The I-TASSER Suite: protein structure and function prediction*. Nat. Meth. 12: 7–8. <https://doi.org/10.1038/nmeth.3213>
- Yu Y., Albrecht K., Groll J., Beilhack A. (2020) *Innovative therapies for invasive fungal infections in preclinical and clinical development*. Expert Opin. Investig. Drugs 29: 961–971. <https://doi.org/10.1080/13543784.2020.1791>